KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Cited by (619)

Items 401–500 of 619

1. Construction of a prognostic glycolysis‐related lncRNA signature for patients with colorectal cancer
   Xinyang Zhong, Xuefeng He, Yaxian Wang, Zijuan Hu, Huixia Huang, Senlin Zhao, Hong Zhang, Ping Wei, Dawei Li · 2022 · Cancer Medicine
2. Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study
   Bo Zhang, Yan Song, Suxia Luo, Xianli Yin, Enxiao Li, Hui Wang, Yifu He, Zhihui Liu, Qingxia Fan, Xinjun Liang et al. · 2023 · Cell Reports Medicine
3. Synergistic Strategies for Lung Cancer Immunotherapy: Combining Phytochemicals and Immune‐Checkpoint Inhibitors
   Quan Gao, Hao Wu, Zhengjun Li, Zijing Yang, Lin Li, Xueni Sun, Qibiao Wu, Xinbing Sui · 2025 · Phytotherapy Research
4. Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?
   Douglas Cartwright, Andrew C Kidd, Sonam Ansel, Maria Libera Ascierto, Pavlina Spiliopoulou · 2025 · International Journal of Molecular Sciences
5. Chimeric peptide-engineered photodynamic PD-L1 degrader for activating colorectal cancer immunity in combination with exosomal PD-L1 inhibition
   Yuxuan Wei, Zuxiao Chen, Wenfeng Zhu, Rongrong Zheng, Chu‐Yu Huang, Ni Yang, Jing Wen, Dawei Zhang, Hong Bo Cheng, Shiying Li · 2025 · Science China Materials
6. MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
   Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis, Elia Aguado-Fraile, Qin Xu, Hiroshi Kondo, Robert T. Manguso, Ilaria Gritti, Bryanna L. Norden, Carolina Noble et al. · 2025 · Clinical Cancer Research
7. Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer
   C. Salva de Torres, Evelyn Elias, Caterina Vaghi, Nadia Saoudi Gonzalez, Ariadna García, Adriana Alcaráz, Marta Rodríguez-Castells, Iosune Baraibar, Javier Ros, Francesc Salvà et al. · 2026 · Cancer Treatment Reviews
8. Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?
   Jiahuan Dong, Yufan Qian, Guangtao Zhang, Lu Lu, Shengan Zhang, Guang Ji, Aiguang Zhao, Hanchen Xu · 2022 · Frontiers in Oncology
9. Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
   Ofra Novoplansky, Sankar Jagadeeshan, Manu Prasad, Ksenia M. Yegodayev, Divyasree Marripati, Raghda Abu Shareb, Yariv Greenshpan, Sooraj Mathukkada, Talal Ben Lulu, Baisali Bhattacharya et al. · 2024 · Journal of Experimental & Clinical Cancer Research
10. Transcriptome Based System Biology Exploration Reveals Homogeneous Tumorigenicity of Alimentary Tract Malignancy
    Yuchen Lu, Jingqi Shi, Zixin Zhang, Jiayi Zhou, Haikun Zhou, Yuancai Feng, Zhenhua Lü, Shuya Yang, Xi-Yang Zhang, Yang Liu et al. · 2021 · Frontiers in Oncology
11. KRAS gene status in gastric signet-ring cell carcinoma patients and acts as biomarker of MEK inhibitor
    Nandie Wu, Ying Huang, Fangcen Liu, Xingyun Xu, Baorui Liu, Jia Wei · 2021 · Journal of Gastrointestinal Oncology
12. Structural, molecular hybridization and network based identification of miR-373-3p and miR-520e-3p as regulators of NR4A2 human gene involved in neurodegeneration
    Jitender Singh, Ashvinder Raina, Namrata Sangwan, Arushi Chauhan, Pramod Avti · 2022 · Nucleosides Nucleotides & Nucleic Acids
13. Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
    Krishnan K. Mahadevan, Ana S. Maldonado, Bingrui Li, Aaron A. Bickert, Adrian Perdyan, Shreyasee V. Kumbhar, Sujan Piya, Amari M. Sockwell, Sami J. Morse, Kent A. Arian et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
14. Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy
    Kentaro Hirade, Noritaka Tanaka, Taisuke Kajino, Yuta Adachi, Ryo Kimura, Hitomi Kasuya, Satoru Kisoda, Tze King Tan, Sho Hayakawa, Takahiko Sato et al. · 2025 · Cell Reports Medicine
15. Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma
    Martina Mang Leng Lei, Carmen Oi Ning Leung, Rainbow Wing Hei Leung, Xiaomeng Wu, Katherine Po Sin Chung, Catherine Yu Jia Gu, Mandy Sze Man Chan, Wing Ki Chau, Quan Hua Mu, Kai Yu Ng et al. · 2025 · Nature Communications
16. Role of senescent tumor cells in building a cytokine shield in the tumor microenvironment: mathematical modeling
    Yangjin Kim, Jun-Ho Lee, Chaeyoung Lee, Sean Edward Lawler · 2022 · Journal of Mathematical Biology
17. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
    Charan Thej Reddy Vegivinti, Cyndi Gonzalez Gomez, Masood Pasha Syed, Morgan Ferrell, Svea Cheng, Aatur Dilip Singhi, Anwaar Saeed, İbrahim Halil Şahin · 2023 · Expert Opinion on Biological Therapy
18. In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors
    Cecilia Pesini, Laura Artal, Jorge Paúl Bernal, Diego Sánchez‐Martínez, Julián Pardo, Ariel Ramírez-Labrada · 2024 · OncoImmunology
19. Resistance to Immunotherapy: Mechanisms and Means for Overcoming
    Mohamad Adham Salkeni, John Y. Shin, James L. Gulley · 2021 · Advances in experimental medicine and biology
20. Identification of pyroptosis-related subtypes, development of a prognostic model, and characterization of tumour microenvironment infiltration in gastric cancer
    Feng Cao, Jingtao Hu, Hongtao Yuan, Pengwei Cao, Yunsheng Cheng, Yong Wang · 2022 · Frontiers in Genetics
21. Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
    Kazunori Aoki, Yukari Nishito, Noriko Motoi, Yasuhito Arai, Nobuyoshi Hiraoka, Tatsuhiro Shibata, Yukiko Sonobe, Yoko Kayukawa, Eri Hashimoto, Mina Takahashi et al. · 2023 · Cancer Research Communications
22. DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care
    Zsuzsanna Suba · 2024 · Cancers
23. The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer
    Rachel P. Riechelmann, Virgilio S. Silva, Celso Abdon Lopes de Mello, Tiago Cordeiro Felismino, Rodrigo Gomes Taboada · 2022 · Current Cancer Drug Targets
24. Leveraging Tumor Microenvironment Infiltration in Pancreatic Cancer to Identify Gene Signatures Related to Prognosis and Immunotherapy Response
    Jiabin Yang, Liangtang Zeng, Ruiwan Chen, Leyi Huang, Zhuo Kui Wu, Min Yu, Yu Zhou, Rufu Chen · 2023 · Cancers
25. Metastatic sites and lesion numbers cooperated to predict efficacy of PD ‐1 inhibitor‐based combination therapy for patients with metastatic colorectal cancer
    Weiqin Jiang, Yinjun He, Wenguang He, Xiang Zhang, Nan Chen, Yandong Li, Weixiang Zhong, Guosheng S. Wu, Xile Zhou, Hanju Hua et al. · 2023 · Cancer Medicine
26. Multi-omics reveals the beneficial effect of Scytosiphon lomentaria fucoidan on glucose and lipid metabolism disorders via regulation of the gut-liver axis in pregnant mice
    Shuangru Tang, Weiyun Zheng, Xiaomeng Ren, Shuang Song, Chunqing Ai · 2024 · Food Bioscience
27. CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer
    Xiaowei He, Ji Liu, Yifan Zhou, Sihan Zhao, Ziming Chen, Zilan Xu, Chunling Xue, Lingxing Zeng, Shuang Liu, Shaoqiu Liu et al. · 2025 · Cell Death and Differentiation
28. Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions
    Gongmin Zhu, Lijiao Pei, Di Ye, Qiulin Tang, Huanji Xu, Feng Bi · 2025 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
29. Differential distribution of immune checkpoints across molecular subtypes of colorectal cancer
    Sofia Edin, Björn Gylling, Xingru Li, Åsa Stenberg, Anna Löfgren‐Burström, Bethany R. Van Guelpen, Agnes Ling, Ingrid Ljuslinder, Richard Palmqvist · 2025 · OncoImmunology
30. Cannabidiol suppresses emergency MDSCs generation by disturbing EEF1B2-mediated C/EBP β protein synthesis in colorectal adenomas
    Jie Pan, Lixin Zhao, Haojie Du, Yuyu Zhu, Xiaofan Sun, Qiang Xu, Haibo Cheng, Hongqi Chen, Yang Sun · 2026 · Journal for ImmunoTherapy of Cancer
31. Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRAS G12C -Mutant NSCLC for Immune Checkpoint Blockade
    Xing Wei, Cristina Blaj, Muhammad Ali Al-Radhawi, Lo Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela Alejandra Moreno Ayala et al. · 2026 · Cancer Discovery
32. Integrated Analysis Identifies Upregulated SAMD9L as a Potential Biomarker Correlating with the Severity of Primary Sjögren’s Syndrome
    Donghai Zhou, Xue Yu, Kai Yu, Yating Ren, Kepeng Yang, Xinchang Wang, Qiao Wang · 2023 · Journal of Inflammation Research
33. Enhanced Apc adenoma formation after epithelial CUL4B deletion by recruitment of myeloid-derived suppressor cells
    Beibei Guo, Yawen Zheng, Yujia Fan, Yang� Yang, Yuxing Wang, Liping Qin, Yachun An, Xiaoran Xu, Xiyu Zhang, Gongping Sun et al. · 2024 · Neoplasia
34. FOXP3 Isoforms Expression in Cervical Cancer: Evidence about the Cancer-Related Properties of FOXP3Δ2Δ7 in Keratinocytes
    Natalia Garcia-Becerra, Marco Ulises Aguila-Estrada, Luis Arturo Palafox-Mariscal, Georgina Hernández‐Flores, Adriana Aguilar‐Lemarroy, Luis Felipe Jave‐Suárez · 2023 · Cancers
35. Single-cell profiling of the copy-number heterogeneity in colorectal cancer
    Shiyu Song, Lin Feng, Kexing Xi, Zhi‐Gang Sun, Deyang Kong, Zhenkai Luo, Wei Pei, Haizeng Zhang · 2023 · Chinese Medical Journal
36. Identification of Cuproptosis-Related Subtypes, Establishment of a Prognostic Signature and Characterization of the Tumor Microenvironment in Gastric Cancer
    Jiazheng Li, Can Kong, Wei Song, Tao Fu · 2023 · International Journal of General Medicine
37. Tumor Copy Number Alteration Burden as a Predictor for Resistance to Immune Checkpoint Blockade across Different Cancer Types
    Karama Asleh, Rodney J. Ouellette · 2024 · Cancers
38. Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies
    Daosong Dong, Yu Xue, Haoran Liu, Jingjing Xu, Jiayan Guo, Wei Guo, Xiang Li, Fei Wang, Dongyong Zhang, Kaiwei Liu et al. · 2025 · Seminars in Cancer Biology
39. Clinical Significance of a Novel Tumor Progression-Associated Immune Signature in Colorectal Adenocarcinoma
    Rui Mao, Fan Yang, Zheng Wang, Chenxin Xu, Qian Liu, Yanjun Liu, Tongtong Zhang · 2021 · Frontiers in Cell and Developmental Biology
40. Assessment of copy number in protooncogenes are predictive of poor survival in advanced gastric cancer
    Meihui Li, Young-Hoon Kim, Tae‐Shin Kim, Nam‐Yun Cho, Jeong Mo Bae, Woo Ho Kim, Gyeong Hoon Kang · 2021 · Scientific Reports
41. Novel Insights into the Role of Kras in Myeloid Differentiation: Engaging with Wnt/β-Catenin Signaling
    Noriko Yokoyama, Hitoshi Nakayama, Kazuhisa Iwabuchi · 2023 · Cells
42. Cyclin E1 overexpression triggers interferon signaling and is associated with antitumor immunity in breast cancer
    Shibo Yu, Chantal Stappenbelt, Mengting Chen, Mirte Dekker, Arkajyoti Bhattacharya, Tineke van der Sluis, Mieke C. Zwager, Carolien P. Schröder, Rudolf S.N. Fehrmann, Marcel A.T.M. van Vugt et al. · 2025 · Journal for ImmunoTherapy of Cancer
43. Nanomedicines: an update of diagnostic and therapeutic applications in multiple cancers
    Sani Jaysing Shinde, Priyanka, Manju Jakhar, Isha Arora, Deepika Sehgal, Mahak, Anupama Kumari, Tamanna Dhiman, Priya, Narender Kumar et al. · 2026 · Journal of drug targeting
44. Arachidonic Acid Metabolism in PMN-MDSCs Suppresses Antitumor Capacity of T Cells in KRAS -Mutant Cholangiocarcinoma
    Jian Lin, Chen Sang, Bin Xiang, X Y Shen, Junmei Zhao, Shengshi Xu, Jiaomeng Pan, Youpei Lin, Liangqing Dong, Qianqian Chu et al. · 2026 · Cancer Discovery
45. Nanomedicine for colorectal cancer therapy by remodeling the immune microenvironment
    Yuxin Wu, Yufei Su, Yuting Wei, Meiqing Shui, Weiqi Li, Lu Yang, Kaipei Luo · 2026 · Journal of Controlled Release
46. Multi Omics Integration in Colorectal Cancer: From Molecular Insights to Precision Oncology
    Zuoliang Liu, Mia Yang Ang, Chin Siang Kue · 2026 · Cancers
47. Macrocarpal I induces immunogenic cell death and synergizes with immune checkpoint inhibition by targeting tubulin and PARP1 in colorectal cancer
    Yaxin Zhang, Huali Li, Yali Zhao, Lingtao Liu, Yi Zhou, Xingyan Pan, Yan-qing Ding, Wenting Liao, Lu Qi, Chengmei Huang et al. · 2025 · Cell Death Discovery
48. Case report: A colorectal cancer patient with microsatellite instability-high and MSH2 germline mutation failed to respond to anti-PD-1 immunotherapy
    Qun Zhang, Jing Ying Hu, Yaping Zhang, Li Li, Ting Wang, Xiaoping Qian · 2022 · Frontiers in Immunology
49. Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients
    Wenjie Zhu, Changlei Wu, Shiqi Hu, Sicheng Liu, Shimin Zhao, Dongdong Zhang, Guisheng Qiu, Xiufeng Cheng, Jun Huang · 2023 · Scientific Reports
50. Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking
    Zhiwu Tan, Mei Sum Chiu, Ming Yue, Hauyee Kwok, Man Ho Tse, Wen Yang, Bohao Chen, Dawei Yang, Dongyan Zhou, You‐Qiang Song et al. · 2023 · Journal of Leukocyte Biology
51. Inflammatory response in gastrointestinal cancers: Overview of six transmembrane epithelial antigens of the prostate in pathophysiology and clinical implications
    Ze-Xuan Fang, Wen-Jia Chen, Zheng Wu, Yan-Yu Hou, Yang-Zheng Lan, Hua-Tao Wu, Jing Liu · 2024 · World Journal of Clinical Oncology
52. An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance
    Lulu Shao, Rashmi Srivastava, Greg M. Delgoffe, Stephen H. Thorne, Saumendra N. Sarkar · 2024 · Cancer Immunology Research
53. The CXCR2 chemokine receptor: A new target for gastric cancer therapy
    Wenyan Kang, Chengkun Wang, Minhui Wang, Meiqi Liu, Wei Hu, Xiaoqiu Liang, Yang Zhang · 2024 · Cytokine
54. Uncovering the Role of Anoikis-Related Genes in Modulating Immune Infiltration and Pathogenesis of Diabetic Kidney Disease
    Jiaqiong Lin, Yan Lin, Xiaoyong Li, Fei He, Qinyuan Gao, Yuanjun Wang, Zena Huang, Fu Xiong · 2024 · Journal of Inflammation Research
55. Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
    Shunli Dong, Cong Ye, Bin Li, Fanglin Lv, Lu Zhang, Shumin Yang, Fang Wang, Mingxian Zhu, Mingxuan Zhou, Fanfan Guo et al. · 2024 · Cancer Immunology Research
56. Identification of T cell dysfunction molecular subtypes and exploration of potential immunotherapy targets in BRAF V600E-mutant colorectal cancer
    Tiefeng Gu, Haonan Qi, Jiaqi Wang, Lifeng Sun, Yu‐Xiong Su, Hanqing Hu · 2025 · Discover Oncology
57. Immunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution
    Yusaku Momoi, Shogo Kumagai, Hiroyoshi Nishikawa · 2025 · International Immunology
58. Tumor-intrinsic TTLL12 drives resistance to cancer immunotherapy via modulating myeloid-derived suppressor cells
    Dong-Wen Chen, Yi‐Kan Cheng, Peisi Li, Xiaojian Wu, Xin-Xin Huang, Jia-Hui Long, Zhizhong Xiong, Chong Chen, Shubiao Ye, Ping Lan · 2025 · Journal for ImmunoTherapy of Cancer
59. TNFAIP2 deficiency drives formation of an immunosuppressive tumor microenvironment and confers resistance to anti-PD-1 therapy in skin cutaneous melanoma
    Yaning Wang, Jinsong Wang, Zhihong Chen, Chiyang Zhong, Hao Luo, Xu Teng · 2025 · Scientific Reports
60. Inflammation and cancer
    Gerardo Guillermo Mackenzie · 2021 · Elsevier eBooks
61. Myeloid-Derived Suppressor Cells and Macrophage Polarization in Cancer Immunotherapy
    Mohammad‐Salar Hosseini, Mohammad Amin Akbarzadeh, Farhad Jadidi‐Niaragh · 2024 · Advances in medical diagnosis, treatment, and care (AMDTC) book series
62. Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer
    Efstathios–Iason Vlachavas, Konstantinos Voutetakis, Vivian Kosmidou, Spyridon Tsikalakis, Spyridon Roditis, Konstantinos Pateas, Ryangguk Kim, Kymberleigh A. Pagel, Stephan Wolf, Gregor Warsow et al. · 2025 · Molecular Oncology
63. Exploring the role of neutrophil extracellular traps in colorectal cancer: Insights from single-cell sequencing
    Zhen-Xi Xu, Fan-Yong Qu, Zheng Zhang, Wen-Yu Luan, Si-Xiang Lin, Yandong Miao · 2025 · World Journal of Gastrointestinal Oncology
64. Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy
    Jielin Liu, Shelley M. Herbrich, Sreyashi Basu, Yulong Chen, Ashwat Nagarajan, Swetha Anandhan, Sangeeta Goswami, Liangwen Xiong, Baoxiang Guan, Padmanee Sharma · 2025 · Science Advances
65. Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial
    Zhan Wang, Bao‐Dong Qin, Chen-Yang Ye, Miaomiao Wang, Lingyan Yuan, Houshan Yao, Xiao‐Dong Jiao, Ke Liu, Wenli Zhou, Wenxing Qin et al. · 2025 · Signal Transduction and Targeted Therapy
66. O-GlcNAcylation of UGDH regulates its activity and remodels the extracellular matrix to facilitate tumor growth
    Bingyi Lin, Junjie Zhou, Didi Geng, Siyuan Chai, Xuanming Zhang, Zengle Zhang, Jiating Hu, Qin Tang, Xiaoming Chen, Wen Yi et al. · 2025 · Cell Death and Differentiation
67. The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma
    Wentong Mei, Yixuan Ding, Chunjing Bian, Yuchen Jia, Chang F. Qu, Zhen Fang, Jie Li, Shuang Liu, Haichen Sun, Xiaoqing Xu et al. · 2025 · Journal of Advanced Research
68. A subset of MMR ‐proficient colon cancers responds to neoadjuvant immunotherapy
    Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli · 2025 · Molecular Oncology
69. Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives
    Tao Shen, Weiyu Fei, Zherui Hu, Miaomiao Pang, Jiaqi Ma, Tingting Zhou, Yanguo Shang · 2025 · Bioorganic Chemistry
70. Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study
    X. Liu, K. Ou, X. Ma, W. Yang, B. Cao, J. Lu, L. Zhang, L. Gao, Q. Wang, W. Zhang et al. · 2026 · ESMO Open
71. Breaching the immune-cold barrier in pMMR/MSS metastatic colorectal cancer: emerging strategies beyond standard care
    Wenkai Kang, Zhiqiang Zhang, Wentao Li, Qingyuan Zhang, Ningning Li, Youheng Jiang, Junjing Zhang, Yulong He · 2026 · Frontiers in Immunology
72. Systematic and precise interventions for KRAS-mutant cancers
    JingHui Liang, JunXi Wu, Yuan Zhang, Hongyu Wang, YiYang Zheng, Qing He · 2026 · Experimental Hematology and Oncology
73. A tumor-intrinsic WNT-inhibitory NOTUM program drives immune resistance in microsatellite stable colorectal cancer
    Julian Chua, Arshdeep Kaur, Fynnis Mitchell, Anneke Korver, Parnika Sakthivel, Elleine Allapitan, Mahdin Uddin, Areeba Maqsood, Naomi Chege, Aralia Leon‐Coria et al. · 2026 · Cell Reports Medicine
74. Myeloid-derived suppressor cells in colorectal cancer: mechanisms of immunosuppression, therapy resistance and therapeutic targeting
    Haoyi Zhang, Wenyue Liu, Yutong Zhang, 陈舒晨, Gongping Sun · 2026 · Frontiers in Cell and Developmental Biology
75. Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer
    Krishnan K. Mahadevan, Ana S. Maldonado, Bingrui Li, Aaron A. Bickert, Adrian Perdyan, Shreyasee V. Kumbhar, Sujan Piya, Amari M. Sockwell, Sami J. Morse, Kent A. Arian et al. · 2026 · Nature Communications
76. Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma
    Xiaqing Li, Shi-Qi Yin, Lin Chen, Aziguli Tulamaiti, Shu-Yu Xiao, Xueli Zhang, Lei Shi, Xiao-Cao Miao, Yang Yan, Xin Xing · 2024 · BMC Cancer
77. CD177 drives the transendothelial migration of Treg cells enriched in human colorectal cancer
    Shouyu Ke, Lei Yi, Yixian Guo, Feng Xie, Yimeng Yu, Haigang Geng, Yiqing Zhong, Danhua Xu, Xu Liu, Fengrong Yu et al. · 2024 · Clinical & Translational Immunology
78. The Chemokine CXCL7 is Correlated with LDH-A and Predicts the Prognosis of Patients with Colorectal Cancer
    Hai Liang, Longhai Li, Baoyu Huang, Rongyan Jiang, Gang Cheng, Shuli Hao, Shuli Hao · 2024 · Frontiers in Bioscience-Landmark
79. Integrative analyses of multi-omics data constructing tumor microenvironment and immune-related molecular prognosis model in human colorectal cancer
    Yifei Li, Hexin Li, Gaoyuan Sun, Siyuan Xu, Xiaokun Tang, Lanxin Zhang, Li Wan, Lili Zhang, Min Tang · 2024 · Heliyon
80. Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
    Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, Ayodeji A. Agbowuro, Christopher M. Brackett · 2025 · Drug Development Research
81. Differential unfolded protein response regulation in KRAS silencing sensitive and innately resistant colorectal cancer cells
    Flávia Martins, Ana L. Machado, Joana Carvalho, Catarina Rodrigues Almeida, Hans Christian Beck, Ana Sofía Carvalho, Vadim Backman, Rune Matthiesen, Sérgia Velho · 2025 · Scientific Reports
82. KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications
    Anita Emami, Pouya Mahdavi Sharif, Nima Rezaei · 2025 · Expert Opinion on Therapeutic Targets
83. Acetylation reader BRD4-driven TXNIP transcription enhances NLRP3 inflammasome activation in PCOS
    Yajing Weng, Yi Zhang, Wei Dong, Zhengquan Zhu, Zou Xiang, Guijun Yan, Hongwei Wang, Yanting Wen, Min Liu, Daojuan Wang et al. · 2025 · Cellular and Molecular Life Sciences
84. Human inborn errors of immunity associated with IRF4
    Romane Thouenon, Sven Kracker · 2023 · Frontiers in Immunology
85. EPRIM: An approach of identifying cancer immune-related epigenetic regulators
    Aiai Shi, Chaohuan Lin, Jilu Wang, Ying’ao Chen, Jinjin Zhong, Jie Lyu · 2023 · Molecular Therapy — Nucleic Acids
86. A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer
    S. Roth, K. Wilson, Robert G Ramsay, Catherine Mitchell, S. Sampurno, Toan Pham, Joseph Cherng Huei Kong, Stephen Q. Wong, A. Heriot, S. Deva et al. · 2024 · Heliyon
87. Colorectal cancer patient outcome is influenced by tumour-adherent bacteria through epigenetic regulation of cardinal genes including PHLPP1
    Iradj Sobhani, Nilmara de Oliveira Alves, Cécile Charpy, Emma Bergsten, Caroline Barau, Amaury Vaysse, Mathias Chamaillard, Shatha Awaad, Aurélien Amiot, Mohammad Sadeghi et al. · 2025 · BMJ Oncology
88. KRAS inhibitors in drug resistance and potential for combination therapy
    Lala S. Rathod, Nikhil S. Sakle, Santosh N. Mokale · 2024 · Tumori Journal
89. KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer
    Fumihiro Terasaki, Shogo Kumagai, Akito Fukuda, Yosuke Tanaka, Takuma Irie, Sachiko Ito, Mihoko Yamada, Shunsuke Onoe, Takashi Mizuno, Toshio Kokuryo et al. · 2025 · International Immunology
90. Polyp of the colon and rectum (K62.1, K63.5, D37.4, D12.0, D12.1, D12.2, D12.3, D12.4, D12.5, D12.6, D12.7, D12.8), adults, children (PROJECT)
    Yu. A. Shelygin, Ачкасов Сергей Иванович, Федоров Евгений Дмитриевич, В. В. Веселов, А. А. Ликутов, E. G. Rybakov, Ilya V. Nazarov, M.Yu. Agapov, N. V. Ageykina, Yu. E. Vaganov et al. · 2025 · Koloproktologia
91. Regulatory Effects of Oncogenes and Tumor Suppressor Genes on Tumor Immune Microenvironment
    Shu-Yi TAN, Jian Zhang · 2025 · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
92. USP25 attenuates the immunosuppressive tumor microenvironment via the deubiquitination of TAB2 in head and neck squamous cell carcinoma
    Xingchen Li, Yidi Jia, Runfang Zhang, Zheng Xu, Chuang Li, Weike Ma, Yang Han, Zheng Chen, Yanqing Li, Qianqian Shi et al. · 2025 · Cell Death Discovery
93. The KDM6B/SLC10A2 Axis Suppresses MDSCs Recruitment via ERK/AP‐1 Signaling in Colorectal Cancer
    Zhibo Hu, Jing Xun, Bin Liu, Xiaolin Jiang, Yingdi Han, Huichao Yang, Qi Gao, Ruifang Gao, Aimin Zhang, Xueliang Wu et al. · 2025 · Advanced Science
94. Loss of MicroRNA-29b promotes DNMT3b-mediated STING downregulation to attenuate radiotherapy-induced antitumor immunity in KRAS-mutated colorectal cancer
    Hsin-Yu Chang, Jhen-Yu Chen, Tao-Wei Ke, Yi-Wen Jiang, Wei-Ze Hong, Yuan-Yao Tsai, Shu‐Fen Chiang, Yu‐Sen Lin, Chi-Hsien Huang, Te-Hong Chen et al. · 2026 · npj Precision Oncology
95. DysUFMylation reprograms immunosuppressive neutrophils to potentiate anti-PD-1 therapy in hepatocellular carcinoma
    Xukang Gao, Min Xu, Zeping Han, Zhiqiu Hu, Yipeng Su, Guoqiang Sun, Wei Chen, Song Qiu, ShuangJian Qiu, Mien‐Chie Hung et al. · 2026 · Cancer Letters
96. Viral mimicry may help explain immunogenic cell death
    Matthew S. Levine, Jiexi Li, Lauren I. R. Ehrlich, Ronald Anthony DePinho, Brent L. Iverson, Jonathan L. Sessler · 2026 · Proceedings of the National Academy of Sciences
97. Targeting colorectal cancer stem-like cells: Overcoming therapeutic resistance and reprogramming the immunosuppressive niche.
    Mahasin Hamid, A. Siddig, R. Suliman, A. Saeed, Ali Mussa, Mohammad A. I. Al-Hatamleh · 2026 · Cancer Letters
98. Clinical complete response to serplulimab plus bevacizumab and chemotherapy in MSS/KRAS-mutant metastatic sigmoid colon adenocarcinoma: a case report and literature review
    Qiao Luo, Haiyan Zhang, Binru Di, Yaowen Liu, Yulin Lei, H Liu, Jianmei Wang, Yuhao Luo · 2026 · Frontiers in Immunology
99. ANALYSIS OF COMMON SOMATIC MUTATIONS IN COLORECTAL CARCINOMA AND ASSOCIATED DYSREGULATED PATHWAYS
    Sobia Hassan, Ambrina Khatoon, Uzma Bukhari, Talat Mirza · 2023 · Journal of Ayub Medical College Abbottabad
100. Defining the Basal and Immunomodulatory Mediator-Induced Phosphoprotein Signature in Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL) Diagnostic Samples
     Aaruni Khanolkar, Guo-Rong Liu, Bridget M. Simpson Schneider · 2023 · International Journal of Molecular Sciences